BCAX trades 265.0% below Wall Street's consensus target of $31.57.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BCAX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Bicara Therapeutics Inc. Common Stock (BCAX) has a Wall Street consensus price target of $31.57, based on estimates from 9 covering analysts. With the stock currently trading at $8.65, this represents a potential upside of +265.0%. The company has a market capitalization of $568M.
Analyst price targets range from a low of $20.00 to a high of $42.00, representing a 70% spread in expectations. The median target of $35.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BCAX trades at a trailing P/E of -3.2x. Analysts expect EPS to grow -25.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 TGTXTG Therapeutics, Inc. | $9.2B | $59.83 | $80.50 | +34.6% | Buy | 59.8x | 13 |
 ERASErasca, Inc. | $5.0B | $14.41 | $21.43 | +48.7% | Buy | — | 11 |
 KYMRKymera Therapeutics, Inc. | $10.8B | $131.73 | $141.53 | +7.4% | Buy | — | 27 |
 MGNXMacroGenics, Inc. | $148M | $2.33 | $9.78 | +319.7% | Buy | — | 22 |
 XNCRXencor, Inc. | $2.7B | $35.75 | $43.86 | +22.7% | Buy | — | 28 |
 ALKSAlkermes plc | $7.7B | $45.90 | $58.70 | +27.9% | Buy | — | 29 |
 RCUSArcus Biosciences, Inc. | $2.3B | $18.28 | $38.80 | +112.3% | Buy | — | 18 |
 AGENAgenus Inc. | $298M | $7.15 | $25.00 | +249.7% | Buy | 26.7x | 12 |
 REGNRegeneron Pharmaceuticals, Inc. | $93.2B | $904.35 | $887.79 | -1.8% | Buy | 13.4x | 49 |
Quick answers to the most common questions about buying BCAX stock.
The consensus Wall Street price target for BCAX is $31.57, representing 265.0% upside from the current price of $8.65. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BCAX has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $31.57 implies 265.0% upside from current levels.
BCAX's current price is $8.65 with a consensus target of $31.57 (265.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $42 for BCAX, while the most conservative target is $20. The consensus of $31.57 represents the median expectation. These targets typically reflect 12-month expectations.
BCAX is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BCAX stock forecast based on 9 Wall Street analysts shows a consensus price target of $31.57, with estimates ranging from $20 (bear case) to $42 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BCAX, with a "Buy" consensus rating and $31.57 price target (265.0% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BCAX analyst price targets range from $20 to $42, a 70% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31.57 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.